{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-26-123960","form_type":"8-K","ticker":"QNRX","cik":"0001671502","company_name":"Quoin Pharmaceuticals, Ltd.","filed_at":"2026-11-06T22:18:56+00:00","discovered_at":"2026-11-06T22:20:00.275115+00:00","generated_at":"2026-11-06T22:20:09.039781+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.72,"calibrated_materiality_score":0.72,"confidence":"high","headline":"Quoin Q3 2026 net loss widens to ~$4.9M as QRX003 interim Phase 2/3 data meet primary endpoint","bullets":["Q3 2026 net loss ~$4.9M vs ~$3.9M a year earlier; nine-month net loss ~$15.2M vs ~$11.5M; cash, equivalents and marketable securities ~$33.2M at Sept 30, 2026.","Interim Phase 2/3 CL-QRX003-004 data: 4 of 6 patients (66.7%) hit the IGA primary endpoint (p=0.0087 vs alpha 0.0215); key secondary p=0.0070; no treatment-related SAEs.","Aug 28 private placement with healthcare-focused institutions for up to ~$50.0M: ~$30.8M upfront plus up to ~$19.2M from ordinary warrant exercises.","FDA cleared the first-ever IND for QRX003 in Peeling Skin Syndrome (July 9), then granted RPD (Sept 8) and Fast Track (Sept 22); EMA added Orphan Drug status Oct 14.","All 20 Netherton Syndrome patients expected enrolled by end-2026 with topline in Q2 2027; first company-sponsored PSS study to start before year end."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-26-123960","json":"https://secwatch.observer/filing/0001104659-26-123960.json","markdown":"https://secwatch.observer/filing/0001104659-26-123960.md","text":"https://secwatch.observer/filing/0001104659-26-123960.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1671502/000110465926123960/0001104659-26-123960-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1671502/000110465926123960/tm2629259d1_8k.htm"},"model":{"generated_by":"deepseek-v4.1-flash:cloud@v2","generated_at":"2026-11-06T22:20:09.039781+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}